
23andMe's Genetic Gamble: Bankruptcy as a Breeding Ground for Savvy Investors
When news broke that 23andMe might be heading towards bankruptcy, it sent shockwaves through the investment landscape. A company that was once worth $6 billion, the sweetheart of the personalized medicine revolution, now on the verge of collapse. It’s tempting to interpret this as a cautionary tale, an indication that...